Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Terumo Corp    4543   JP3546800008

TERUMO CORP (4543)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Terumo : Expands Production in Asia New Factory Established and Existing Facilities Expanded in Vietnam and the Philippines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/10/2012 | 08:13am CEST
May 10, 2012

Terumo Corporation (TOKYO:4543) announced today that it will expand its production facilities in Asia to meet anticipated sales increases in the medium to long term, based on its corporate growth strategy. Terumo Corporation will establish a new factory in Vietnam, its second in the country, as well as expand the production scale of existing factories in Vietnam and the Philippines. The total amount invested will be 15 billion yen.

The new factory in Vietnam will produce blood management products such as blood bags to meet growing global demand, especially in emerging countries.
In cooperation with Ashitaka factory (Shizuoka prefecture) and the new Yamaguchi factory in Japan (operation to be started in 2015), the existing factory in Vietnam will expand the production scale of interventional systems products, sales of which have been growing at a double-digit pace. The company will also establish a new production building at the existing factory in the Philippines to cope with needed production increases of syringes and needles.
To improve its global competitiveness, Terumo Corporation is seeking to enhance the production capacity across all of its three business areas: Cardiac & Vascular, General Hospital, and Blood Management.

Terumo Corporation's global production system

Terumo Corporation is accelerating its growth globally, and plans to increase the percent of production done outside Japan in line with the growth in the share of net sales outside Japan, which already account for over half of the total. Accordingly, the company has positioned factories in Asia as its global production center and is already producing a broad range of products in China, the Philippines, and Vietnam.
On another front, certain highly advanced and precise production technologies are difficult to transfer outside of Japan. The company has designated factories in Japan as mother production factories that develop and refine core manufacturing technologies to underpin product improvement.
Terumo Corporation will continue to enhance its global production system in factories in Asia and Japan to meet growing global demand while increasing cost competitiveness.

Factories Overview 1. Vietnam: a new factory to be established

In April 2012, Terumo BCT was established through the integration of CaridianBCT and Terumo Transfusion, following Terumo Corporation's acquisition of CaridianBCT in April 2011. The company will establish a new factory in Vietnam to produce blood management products to meet growing global demand, especially in emerging countries. The factory will be its sixth production facilities of blood management products, following ones in Japan, U.S., UK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TERUMO CORP
06/20TERUMO : Azur Coils
AQ
06/20TERUMO : Acquires CE Marking for Kanshas Drug Coated Balloon Catheter for Lower ..
PU
06/19TERUMO : 100 pcs Pigtail catheter, 5F Terumo #RH*5SP0061M
AQ
06/19TERUMO : Purchase of Medical, Dental and Laboratory Supplies for the Use of MHO
AQ
06/06TERUMO : Supply and Delivery of Various Medical Supplies
AQ
06/06TERUMO : 60 pcs 5F JR4 Terumo #RH*JR4000M
AQ
06/01+13% CAGR GROWTH TO BE ACHIEVED BY M : Focusing on Top Key Vendors like Tuttnaue..
AQ
05/29TERUMO : Supply and Delivery of Various Medical Supplies
AQ
05/25TERUMO : Procurement of Medicines and Medical Suppliesfor MHO Programs and PUP M..
AQ
05/25TERUMO : to Launch the Ultimaster Tansei Drug Eluting Stent in Europe
PU
More news
News from SeekingAlpha
02/09Terumo Corp. ADR 2018 Q3 - Results - Earnings Call Slides 
2017HAEMONETICS : Revisiting The Company's Outlook 
2016HAEMONETICS : Investor Patience Is Wearing Thin 
2016Terumo Corp. ADR 2017 Q2 - Results - Earnings Call Slides 
2016Abbott's Vascular Products Sale Likely Done To Address Regulatory Concerns 
Financials ( JPY)
Sales 2019 616 B
EBIT 2019 -
Net income 2019 83 203 M
Debt 2019 134 B
Yield 2019 0,84%
P/E ratio 2019 28,36
P/E ratio 2020 25,87
EV / Sales 2019 4,34x
EV / Sales 2020 4,01x
Capitalization 2 536 B
Chart TERUMO CORP
Duration : Period :
Terumo Corp Technical Analysis Chart | 4543 | JP3546800008 | 4-Traders
Technical analysis trends TERUMO CORP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 6 734  JPY
Spread / Average Target 0,81%
EPS Revisions
Managers
NameTitle
Shinjiro Sato President, CEO & Representative Director
Takayoshi Mimura Chairman
Ryo Nishihata Chief Accounting & Financial Officer
Hiroaki Kasukawa CTO, Executive Officer, GM-Research & Development
Katsuya Takeuchi Executive Officer & Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
TERUMO CORP24.16%23 057
MEDTRONIC PLC7.26%117 660
BAXTER INTERNATIONAL14.98%39 970
ALIGN TECHNOLOGY58.99%28 314
ZIMMER BIOMET HOLDINGS-7.59%22 718
HOYA CORPORATION10.76%22 046